Skip to main content

Table 1 Clinical studies that reported DPP-4 inhibitors in patients with T2DM and COVID-19

From: Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications

First author; year; Country Simple size T2M (n.%) DPP-4 i (n.%) Age (years)a Male (%) Outcomes In-hospital death (n.%)
Retrospective studies
Chen et al. 2020.
China [87]
904 136 (15.0) 20 (14.7) 66.0 (56.0–73.0) NR Hospital stay (days)
22 (19.3–29.0)
5 (25.0)
Xu et al. 2020.
China [88]
364 114 (31.3) 7 (6.1) 66.0 (57–73) 54.4 Lower ventilation score 7 (100.0)
Zhu et al. 2020.
China [89]
7337 952 (12.9) 55 (6.8) NR NR 20% well controlled
Rhee et al. 2020.
South Korea [90]
5080 832 (16.3) 263 (31.6) 63.69 (12.2) 56.65 Intensive care 3.42% 4.39
Multicenter observational study
Cariou et al. 2020.
France  [2]
1317 1166 (88.5) 285 (21.6) 69.8 (13.0) 64.9 Tracheal intubation and/or death within 7 days of admission
OR 1.01 (0.75, 1.34)
OR
0.85 (0.55, 1.32)
Case–control study
Fadini et al. 2020
Italy [91]
403 85 (21.1) 9 (10.6) 72.2 (12.8) 77.8 ICU admittance 33.3%
Semi-intensive care 44.4%
11.1
  1. NR No reported, ICU intensive care unit
  2. aAge was reported as range; median ± SD